Comparison of Propranolol and Venlafaxine in Treatment of Vestibular Migraine
Launched by HASEKI TRAINING AND RESEARCH HOSPITAL · Jan 29, 2015
Trial Information
Current as of May 05, 2025
Completed
Keywords
ClinConnect Summary
Vestibular migraine (VM) is a condition of episodic vertigo linked to migrainous symptoms described by Nueuhauser et al. in 2001. Some subjects benefit behavior and diet modification and controls of their symptoms. Anti-migrainous medication for prophylactic aim is given subjects who do not benefit life-style improvement. However, there is absence of sufficient evidence for treatment of VM.
In this study the investigators aimed to evaluated effectiveness of prophylactic treatment venlafaxine by comparing propranolol in VM. The investigators also aimed to investigate if the effectiveness of...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • vestibular migraine does not respond lifestyle and dietary modification
- Exclusion Criteria:
- • known allergic reaction to venlafaxine or propranolol
- • under the care of psychiatrist
- • pregnancy or intention to become pregnant
- • presence significant illness or medical condition such as cancer, liver or kidney failure
- • certain medical conditions with possible adverse effects with propranolol or venlafaxine following as: AV block or bradyarrhythmia; astma or COPD; diabetes mellitus.
About Haseki Training And Research Hospital
Haseki Training and Research Hospital is a leading healthcare institution dedicated to advancing medical research and improving patient care through innovative clinical trials. Located in Istanbul, Turkey, the hospital combines extensive clinical expertise with a commitment to excellence in research, providing a collaborative environment for healthcare professionals and researchers. With a focus on a wide range of medical disciplines, Haseki Hospital aims to contribute to the scientific community by facilitating rigorous clinical studies that adhere to the highest ethical standards, ultimately enhancing treatment options and outcomes for patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Istanbul, , Turkey
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials